Trials / Terminated
TerminatedNCT03045302
Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly
A Phase IIa, Open-label, Single-arm, Two Stage, Multi-centre Study to Investigate the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Repeated Subcutaneous Administration of BIM23B065 in Subjects With Acromegaly
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the protocol is evaluate the safety, the pharmacodynamics and the pharmacokinetic of repeated administration of BIM23B065 in subjects with acromegaly.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BIM23B065 | Subcutaneous twice a day or three times a day administration of BIM23B065. Dose will be 0.4, 0.6, 0.8 or 1 mg (twice a day or three times a day). |
Timeline
- Start date
- 2017-01-26
- Primary completion
- 2017-05-17
- Completion
- 2017-06-02
- First posted
- 2017-02-07
- Last updated
- 2019-03-08
- Results posted
- 2019-03-08
Locations
6 sites across 4 countries: Belgium, Hungary, Serbia, Ukraine
Source: ClinicalTrials.gov record NCT03045302. Inclusion in this directory is not an endorsement.